ATV 1601
Alternative Names: ATV-1601Latest Information Update: 12 Aug 2025
At a glance
- Originator Atavistik Bio
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein c-akt inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I HER2 negative breast cancer; Solid tumours
Most Recent Events
- 04 Aug 2025 Phase-I clinical trials in HER2-negative-breast-cancer (Late-stage disease, Combination therapy, Metastatic disease) in USA (PO) (NCT07038369)
- 04 Aug 2025 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Recurrent, Combination therapy, Monotherapy) in USA (PO)
- 26 Jun 2025 Atavistik Bio plans a first-in-human phase Ia/Ib trial for Solid tumours and HER2-negative breast cancer (Late-stage disease, Metastatic disease, Recurrent, Combination therapy, Monotherapy) in USA (PO) , (NCT07038369)